Body mass index does not influence human epididymis protein 4 concentrations in serum

Clinica Chimica Acta

Volumn 446, Issue , 2015, Pages 163-164

  Ferraro, Simona ^a   Borille, Simona ^a   Caruso, Simone ^a   Boggio, Anna ^a   Muzio, Fulvio ^a   Rizzi, Andrea ^a   Panteghini, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CREATININE; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER; ORAL CONTRACEPTIVE AGENT; PROTEIN; WFDC2 PROTEIN, HUMAN;

ADULT; AGE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OBESITY; ORAL CONTRACEPTIVE USE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; WEIGHT REDUCTION; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PREMENOPAUSE; REGRESSION ANALYSIS;

ADULT; BODY MASS INDEX; CA-125 ANTIGEN; CONTRACEPTIVES, ORAL, HORMONAL; CREATININE; FEMALE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; OBESITY; PREMENOPAUSE; PROTEINS; REGRESSION ANALYSIS;

EID: 84928746194     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.04.028     Document Type: Letter

References (7)

1. Ferraro S., Braga F., Lanzoni M., et al. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 2013, 66:273-281.
2. Ferraro S., Schiumarini D., Panteghini M. Human epididymis protein 4: factors of variation. Clin Chim Acta 2015, 438:171-177.
3. Bolstad N., Øijordsbakken M., Nustad K., et al. Human epididymis protein 4 reference limits and natural variation in Nordic reference population. Tumor Biol 2012, 33:141-148.
4. Lowe K.A., Shah C., Wallace E., et al. Effect of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy post-menopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:2480-2487.
5. Urban N., Thorpe J.D., Bergan L.A., et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 2011, 103:1630-1634.
6. Hess L.M., Barakat R., Tian C., et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2007, 107:260-265.
7. Urban N., Thorpe J., Karlan B.Y., et al. Interpretation of single and serial measures of HE4 and CA-125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:2087-2094.